03/08/2006

Alexza Pharmaceuticals, Inc. Sets Price for Initial Public Offering

Palo Alto, California - March 8, 2006 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today the initial public offering of 5,500,000 shares of common stock at a price of $8 per share. Alexza Pharmaceuticals’ common stock is expected to begin trading on the NASDAQ National Market under the trading symbol ALXA on Wednesday, March 8, 2006. All shares are being offered by Alexza Pharmaceuticals.

The underwriters of the offering are Piper Jaffray & Co. and Pacific Growth Equities, LLC, acting as joint book running managers, and RBC Capital Markets and JMP Securities, acting as co-managers. Alexza Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 8, 2006. This offering is being made by means of written prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained from the prospectus department of either Piper Jaffray & Co. (800 Nicollet Mall, Suite 800, Attention: Equity Capital Markets, Minneapolis, MN 55402, by phone at 612.303.6220 or by fax at 612.303.1070), Pacific Growth Equities, LLC (C/O Prospectus Department, One Bush Street, Suite 1700, San Francisco, CA 94104, by phone at 415.274.6819 or by fax at 415.274.6887), RBC Capital Markets (One Liberty Plaza, New York, NY 10006, by phone at 212.858.7000 or by fax at 212.428.6200) or JMP Securities (600 Montgomery Street, Suite 1100, San Francisco, CA 94111, by phone at 415.835.8900 or by fax at 415.835.8910).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alexza Pharmaceuticals
Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

Contact:
Thomas B. King
President & CEO
650.687.3900
tking@alexza.com